The verdict
Our read at a glance.
Whether DES(1-3) IGF-1, a more potent laboratory form of IGF-1, produces the muscle and recovery benefits it is marketed for, and whether such use is safe.
- The signal
- In cells and animals, DES(1-3) IGF-1 is more potent than natural IGF-1 because it escapes the binding proteins that normally limit IGF-1 activity. This makes it useful in the laboratory. There are no human therapeutic trials, so there is no evidence it builds muscle safely or effectively in people.
- The unknown
- Whether a more potent, less-regulated IGF-1 does anything beneficial in healthy people, and what risks come from chronically amplifying IGF-1 signaling.
- Our read
- Another potent IGF-1 lab reagent sold as a muscle peptide, with no human treatment evidence. Its laboratory potency is real, but that is not a safe or proven human therapy, and amplifying IGF-1 signaling carries genuine theoretical risk.
The mechanism
How it works.
DES(1-3) IGF-1 is insulin-like growth factor 1 with its first three amino acids removed from one end. That short deletion sharply weakens its binding to the IGF binding proteins that normally keep most IGF-1 inactive in reserve, so more of it reaches the IGF-1 receptor and signals more strongly than the natural hormone. This extra potency is useful for laboratory and cell-culture work, but it has never been tested as a controlled treatment in people.
Safety & regulatory boundary
The consequential part.
DES(1-3) IGF-1 is a research reagent, not an approved drug, with no human therapeutic trials. Products sold for muscle building are unapproved gray-market chemicals of uncertain identity and purity. Strongly amplifying IGF-1 signaling carries theoretical risks around tissue overgrowth and cancer pathways that have not been characterized for this use. The approved IGF-1 medicine, mecasermin, is a different product used under medical supervision for rare growth disorders.
What's next
What we're watching.
Whether DES(1-3) IGF-1 ever enters any controlled human study, which would be the first real safety or efficacy data.
Context
Why this is discussed.
IGF-1 drives tissue and muscle growth, and a more potent, less-restrained version is marketed as a stronger shortcut to those effects.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE3 · COMPLETED · 2019-05-20
ClinicalTrials.gov · PHASE2 · COMPLETED · 2016-03-31
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2019-07-04
ClinicalTrials.gov · PHASE1 · TERMINATED · 2022-05-18
ClinicalTrials.gov · PHASE2 · RECRUITING · 2019-05-31
ClinicalTrials.gov · PHASE3 · TERMINATED · 2022-03-04
ClinicalTrials.gov · ENROLLING_BY_INVITATION · 2022-03-16
ClinicalTrials.gov · NA · COMPLETED · 2015-10
Indexed literature (PubMed)12
Ballard FJ et al. · Int J Biochem Cell Biol · 1996
Aron DC · Biofactors · 1992
Sherwin RS et al. · Horm Res · 1994
Kiess W et al. · Horm Res · 1994
Adachi Y et al. · Novartis Found Symp · 2004
Remacle-Bonnet M et al. · Int J Cancer · 1992
Gillespie C et al. · J Endocrinol · 1990
Gustafsson H et al. · Biochem Biophys Res Commun · 2001
Grinspoon S et al. · J Clin Endocrinol Metab · 1995
Rutter LM et al. · J Anim Sci · 1991
Lindgren BF et al. · Acta Endocrinol (Copenh) · 1993
Hirschberg R et al. · J Am Soc Nephrol · 1992
Keep reading